| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
75,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Xenon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing therapeutics for patients with neurological disorders. Co.'s product pipeline of neurology-focused therapies focus on epilepsy. Co.'s product candidates include: XEN1101, a Kv7 potassium channel opener for the treatment of epilepsy and potentially other neurological disorders, such as major depressive disorder; and XEN496, a Kv7 potassium channel opener for the treatment of KCNQ2 developmental and epileptic encephalopathy. In addition, Co. has a license and collaboration agreement with Neurocrine Biosciences Inc. to develop NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of epilepsy.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
22,229 |
48,805 |
236,705 |
576,095 |
| Total Sell Value |
$1,027,488 |
$2,098,369 |
$9,481,770 |
$22,449,223 |
| Total People Sold |
3 |
4 |
7 |
10 |
| Total Sell Transactions |
3 |
6 |
11 |
22 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Empfield James R. |
EVP, Drug Discovery |
• – – |
2022-03-04 |
4 |
OE |
$8.40 |
$210,000 |
D/D |
25,000 |
35,000 |
|
- |
|
| Kenney Christopher John |
Chief Medical Officer |
• – – |
2022-01-21 |
4 |
B |
$28.81 |
$20,167 |
D/D |
700 |
700 |
2.74 |
- |
|
| Azab Mohammad |
Director |
– • – |
2021-12-15 |
4 |
OE |
$3.67 |
$11,326 |
D/D |
3,086 |
66,819 |
|
- |
|
| Patou Gary |
Director |
– • – |
2021-12-08 |
4 |
OE |
$3.67 |
$7,549 |
D/D |
2,057 |
25,630 |
|
- |
|
| Von Seggern Christopher |
Chief Commercial Officer |
• – – |
2021-12-06 |
4 |
B |
$24.40 |
$97,600 |
D/D |
4,000 |
4,000 |
2.74 |
- |
|
55 Records found
|
|
Page 3 of 3 |
|
|
